The company's app provides injection follow-ups, blood sugar level measurement, and automated recording of insulin units and blood glucose levels. It offers remote monitoring and coordination for healthcare professionals to track and educate their patients more accurately, efficiently, and productively. Diabnext's platform enables remote monitoring, coordination, therapeutic education, and analytics of data related to blood glucose, insulin, diet, and physical activity automatically through connected health devices. The company was acquired by Glooko in March 2022 and is now marketed under the name Glooko XT.